This week in drug discovery (14-18 October)
News round-up for 14-18 October by DDW Senior Digital Content Editor Diana Spencer.
As we are halfway through Breast Cancer Awareness Month, our news highlights this week focus on studies that could advance the treatment of cancer in the future, including a new understanding of cancer drug resistance, and novel therapeutics like radioimmunotherapy, RBM39 degraders and peptide-drug conjugates.
The top stories:
Radioimmunotherapy drug results to be shared at EANM
Akiram Therapeutics will reveal its research findings on radioimmunotherapy drug candidate AKIR001 at the European Association of Nuclear Medicine (EANM) Congress 2024 in Hamburg, from 19-23 October.
RBM39 degrader offers “promising approach” in solid tumours
TechBio Recursion will be launching a Phase I/II clinical trial of REC-1245 for the treatment of biomarker-enriched solid tumours and lymphoma, following the go-ahead from the US Food and Drug Administration (FDA).
New study aims to find cancer cures in survivors’ immune cells
Etcembly has launched a new research study aiming to uncover new targets for cancer therapies by analysing the immune cells of cancer survivors.
Peptide-drug conjugate demonstrates antitumour activity
Cybrexa Therapeutics has dosed the first patient in a Phase II trial of its peptide-drug conjugate (PDC) CBX-12 in ovarian cancer.
Drug resistance study boosts discovery of next-generation cancer drugs
New research has detailed each type of cancer mutation that causes drug resistance, helping to uncover targets for drug development and identify potential effective second-line therapies.
